SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 22nd, 2019 • Generex Biotechnology Corp • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 28, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the “Buyer”).
COMMON STOCK PURCHASE WARRANT GENEREX BIOTECHNOLOGY CORPORATIONCommon Stock Purchase Warrant • February 22nd, 2019 • Generex Biotechnology Corp • Pharmaceutical preparations • Nevada
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the $750,000.00 convertible promissory note to the Holder (as defined below) of even date) (the “Note”), FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to 57,143 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated January 2
AMENDMENT #1 TO THE SECURITIES PURCHASE AGREEMENT, CONVERTIBLE PROMISSORY NOTE, AND COMMON STOCK PURCHASE WARRANT DATED JANUARY 28, 2019Securities Purchase Agreement • February 22nd, 2019 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS AMENDMENT #1 (the “Amendment”) to the SPA (as defined below), Note (as defined below), and Warrant (as defined below) is made effective as of February 13, 2019, by and between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “Holder”) (collectively the “Parties”).
